Risperidone treatment does not change the percentage or activation of splenic myeloid populations during EAE.

Abstract

<p><b>a.</b> Gating strategy for the major splenic myeloid populations. <b>b.</b> Red pulp macrophages (RP MΦ) and DC but not white pulp macrophages express MHC II and CD40. Shown are representative plots from a vehicle-treated, immunized mouse. <b>c.</b> Immunization induces an increase in neutrophils and red pulp macrophages and risperidone alone enhances splenic DC. Splenocytes were isolated from risperidone- and vehicle-treated, unimmunized and immunized mice 15 days post-immunization and gated as shown in <b>a</b>. Shown are the means and SEM of individual mice from three experiments (n = 10–15 per group). **p&lt;0.01 and ***p&lt;.001 by one-way ANOVA with Newman-Keul's multiple comparison test. <b>d.</b> No difference in the number of total splenocytes is observed. Splenocytes were isolated from risperidone- and vehicle-treated, unimmunized and immunized mice 15 days post-immunization and live cells counted by the trypan blue exclusion assay. Shown are the means and SEM of individual mice from three experiments (n = 10–15 per group). <b>e–f.</b> Immunization increases the expression of I-A on RP MΦ (<b>e</b>) and DC (<b>f</b>) and CD40 on DC (<b>h</b>) and risperidone does not alter these levels. Splenocytes were isolated from risperidone- and vehicle-treated, unimmunized and immunized mice 15 days post-immunization and gated as shown in <b>a</b>. The expression (ΔMFI compared to isotype controls) of I-A and CD40 are expressed as % of vehicle-treated, unimmunized group. Shown are the means and SEM of individual mice from three experiments (n = 10–15 per group). *p&lt;0.05 and **p&lt;0.01 by two-way ANOVA to distinguish overall drug and immunization effects.</p